Table 1.
Characteristics of clinical trials of COVID-19 convalescent plasma
| Total trials (n = 48) |
Controlled studies (n = 29) |
|||||
|---|---|---|---|---|---|---|
| Trials | n, treatment armsb | Trials | n, treatment armsb | Planned completion by Dec 31, 2020 (trials) | n, completed trials by Dec 31, 2020b | |
| Country | ||||||
| China | 11 | 345 | 9 | 320 | 7 | 210 |
| USA | 11 | 906 | 4 | 971 | 0 | 0 |
| Iran | 7 | 302 | 6 | 272 | 5 | 257 |
| Othera | 19 | 3861 | 10 | 1632 | 8 | 1322 |
| Critical/severe cases | 33 | 4440 | 21 | 1965 | 16 | 1530 |
| Actively recruiting as of April 23, 2020 | 23 | 1364 | 17 | 1199 | 13 | 779 |
a
Other: Mexico, Ireland, Mexico, Pakistan, Egypt, Canada, Saudi Arabia, Italy, India, France, Hungary, Spain, Denmark, Netherlands, Columbia, Germany.
b
If the study did not specify the sampling ratio, a 1:1 ratio was assumed per arm.